Immunocore Holdings PLC (IMCR) — 10-Q Filings
All 10-Q filings from Immunocore Holdings PLC. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 6, 2026
-
Immunocore's Therapy Sales Soar 29% Amidst Q3 Net Loss
— Nov 6, 2025 Risk: medium
Immunocore Holdings plc reported a significant increase in revenue from the sale of therapies, reaching $103.693 million for the three months ended September 30 -
Immunocore Swings to Profit on Soaring Collaboration Revenue
— Aug 7, 2025 Risk: medium
Immunocore Holdings plc reported a significant increase in total revenue for the six months ended June 30, 2025, reaching $115.0 million, up from $85.0 million -
Immunocore Files Q1 2025 10-Q
— May 7, 2025 Risk: medium
Immunocore Holdings plc filed its 10-Q for the period ending March 31, 2025. The company reported revenue from the sale of therapies and collaboration revenue f -
Immunocore Reports Strong Q3 Revenue Growth
— Nov 6, 2024 Risk: medium
Immunocore Holdings plc filed a 10-Q for the period ending September 30, 2024. The company reported product revenue of $10.5 million for the third quarter of 20 -
Immunocore Holdings plc Q2 2024 10-Q Filing
— Aug 8, 2024 Risk: medium
Immunocore Holdings plc filed its 10-Q for the period ending June 30, 2024. The company reported revenue from product sales and collaboration agreements. Specif -
Immunocore Holdings plc Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: low
Immunocore Holdings plc (IMCR) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Immunocore Holdings plc filed a 10-Q report for the period ending Ma
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX